APA (7th ed.) Citation

M, K., J, H., A, E., C, F., D, B., S, M., . . . L, V. (2013). Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: A NICE single technology appraisal. PharmacoEconomics, 31(1), 15. https://doi.org/10.1007/s40273-012-0006-5

Chicago Style (17th ed.) Citation

M, Kilonzo, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, and Vale L. "Pazopanib for the First-line Treatment of Patients with Advanced And/or Metastatic Renal Cell Carcinoma: A NICE Single Technology Appraisal." PharmacoEconomics 31, no. 1 (2013): 15. https://doi.org/10.1007/s40273-012-0006-5.

MLA (9th ed.) Citation

M, Kilonzo, et al. "Pazopanib for the First-line Treatment of Patients with Advanced And/or Metastatic Renal Cell Carcinoma: A NICE Single Technology Appraisal." PharmacoEconomics, vol. 31, no. 1, 2013, p. 15, https://doi.org/10.1007/s40273-012-0006-5.